Hims & Hers Health Inc (NYSE: HIMS)’s stock price has soared by 1.64 in relation to previous closing price of 16.46. Nevertheless, the company has seen a gain of 7.38% in its stock price over the last five trading days. fool.com reported 2024-08-22 that After a strong start to the year, the stock is down 30% since June.
Is It Worth Investing in Hims & Hers Health Inc (NYSE: HIMS) Right Now?
Hims & Hers Health Inc (NYSE: HIMS) has a price-to-earnings ratio of 223.66x that is above its average ratio. Additionally, the 36-month beta value for HIMS is 1.08. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HIMS is 164.09M and currently, short sellers hold a 11.74% ratio of that float. The average trading volume of HIMS on August 26, 2024 was 10.46M shares.
HIMS’s Market Performance
The stock of Hims & Hers Health Inc (HIMS) has seen a 7.38% increase in the past week, with a -28.04% drop in the past month, and a 5.69% gain in the past quarter. The volatility ratio for the week is 6.03%, and the volatility levels for the past 30 days are at 7.43% for HIMS. The simple moving average for the past 20 days is -4.23% for HIMS’s stock, with a 20.30% simple moving average for the past 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with Needham repeating the rating for HIMS by listing it as a “Buy.” The predicted price for HIMS in the upcoming period, according to Needham is $24 based on the research report published on August 22, 2024 of the current year 2024.
Citigroup gave a rating of “Neutral” to HIMS, setting the target price at $20 in the report published on May 22nd of the current year.
HIMS Trading at -16.88% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.00% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 6.03%, as shares sank -23.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.35% lower at present.
During the last 5 trading sessions, HIMS rose by +7.38%, which changed the moving average for the period of 200-days by +166.40% in comparison to the 20-day moving average, which settled at $17.22. In addition, Hims & Hers Health Inc saw 87.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Boughton Soleil, who sale 2,334 shares at the price of $16.71 back on Aug 20 ’24. After this action, Boughton Soleil now owns 162,141 shares of Hims & Hers Health Inc, valued at $39,001 using the latest closing price.
Boughton Soleil, the Officer of Hims & Hers Health Inc, proposed sale 2,334 shares at $16.71 during a trade that took place back on Aug 20 ’24, which means that Boughton Soleil is holding shares at $39,001 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.0 for the present operating margin
- 0.78 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.02. The total capital return value is set at 0.01. Equity return is now at value 5.31, with 4.16 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 11.2. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 2.71.
Currently, EBITDA for the company is -23.95 million with net debt to EBITDA at -7.39. When we switch over and look at the enterprise to sales, we see a ratio of 3.16. The receivables turnover for the company is 192.24for trailing twelve months and the total asset turnover is 2.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.68.
Conclusion
In conclusion, Hims & Hers Health Inc (HIMS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
